CUE Cue Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1645460 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY401.9%
TTM net income YoY-448.5%
TTM EPS YoY-107.1%
Revenue 3-yr CAGR110.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-387.7%
Net margin-579.9%
FCF margin-143.7%
EBITDA margin-384.0%
Returns
ROE-800.4%
ROA-418.0%
ROIC (approx.)—
Asset turnover0.72x
Leverage & solvency
Liabilities / assets42.9%
Debt / equity0.00x
Current ratio3.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-314.6%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $132,000 | $7.88M | $5.69M | $21.94M | $2.15M | $2.95M | $421,000 | $1.58M |
| R&D expense | $17.02M | $49.01M | $6.90M | $16.53M | $4.75M | $7.91M | $8.55M | $7.18M |
| SG&A expense | $29.83M | $46.56M | $4.15M | $3.45M | $4.94M | $3.68M | $4.17M | $4.02M |
| Operating income | -$47.10M | -$87.69M | -$5.35M | $1.98M | -$7.59M | -$8.63M | -$12.30M | -$9.63M |
| Interest expense | — | — | — | $2,000 | $33,000 | $33,000 | $100,000 | — |
| Net income | -$50.02M | -$153.07M | -$5.18M | $1.58M | -$7.45M | -$8.48M | -$12.26M | -$9.50M |
| EBITDA | -$47.07M | -$87.66M | -$4.79M | $2.66M | -$7.52M | -$8.54M | -$12.20M | -$9.54M |
| EPS (basic) | -4.74 | -24.14 | -1.08 | — | -2.22 | -2.67 | -4.95 | — |
| EPS (diluted) | -4.74 | -24.14 | -1.08 | — | -2.22 | -2.67 | -4.95 | — |
| Weighted avg. shares (diluted) | 10.56M | 6.34M | 4.81M | — | 3.36M | 3.18M | 2.48M | — |
| Banking | ||||||||
| Net interest income | -$2,000 | -$5,000 | -$4,000 | -$51,000 | -$75,000 | -$45,000 | -$128,000 | -$153,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $57.94M | $17.39M | $16.38M | $27.14M | $11.70M | $27.49M | $13.14M | $22.46M |
| Short-term investments | — | — | — | — | $6.97M | — | — | $0 |
| Receivables | $5.13M | $5.38M | $5.35M | $5.55M | $387,000 | $532,000 | $0 | $945,000 |
| Current assets | $66.71M | $26.62M | $26.39M | $36.98M | $25.82M | $30.84M | $15.93M | $25.14M |
| PP&E, net | $225,000 | $255,000 | $288,000 | $241,000 | $307,000 | $454,000 | $523,000 | $471,000 |
| Total assets | $67.25M | $30.71M | $30.88M | $42.21M | $31.64M | $40.71M | $22.25M | $32.19M |
| Current liabilities | $19.73M | $21.22M | $7.39M | $13.49M | $15.52M | $19.25M | $15.50M | $13.69M |
| Short-term debt | — | — | — | — | — | — | $100,000 | $37,000 |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total debt | — | — | — | — | — | — | — | $37,000 |
| Total liabilities | $28.86M | $28.40M | $9.27M | $15.78M | $18.40M | $22.55M | $15.67M | $14.69M |
| Shareholders' equity | $38.40M | $2.31M | $21.61M | $26.43M | $13.25M | $18.16M | $6.58M | $17.50M |
| Net debt | — | — | — | — | — | — | — | -$22.42M |
| Shares outstanding | 7.75M | 5.23M | 3.26M | 3.22M | 77.78M | 76.45M | 61.82M | 61.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.08M | -$29.00M | -$10.94M | -$1.08M | -$9.02M | -$3.42M | -$8.17M | -$9.03M |
| Capital expenditure | $0 | $0 | $121,000 | $0 | $0 | $27,000 | $150,000 | $2,000 |
| Free cash flow | -$10.08M | -$29.00M | -$11.06M | -$1.08M | -$9.02M | -$3.44M | -$8.32M | -$9.03M |
| Investing cash flow | $0 | $0 | -$121,000 | $7.02M | -$6.77M | -$27,000 | -$150,000 | -$1,000 |
| Financing cash flow | $50.63M | $30.02M | $306,000 | $9.49M | $1,000 | $17.80M | -$1.00M | -$932,000 |
| Depreciation & amortization | $28,000 | $33,000 | $566,000 | $678,000 | $76,000 | $97,000 | $101,000 | $98,000 |
| Stock-based compensation | $35.48M | $23.84M | $48,000 | $610,000 | $1.53M | $1.26M | $1.34M | $1.56M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.